{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T05:05:34Z","timestamp":1782277534770,"version":"3.54.5"},"reference-count":88,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.tube.2008.06.001","type":"journal-article","created":{"date-parts":[[2008,8,4]],"date-time":"2008-08-04T14:02:12Z","timestamp":1217858532000},"page":"410-419","source":"Crossref","is-referenced-by-count":17,"title":["Inhibition of M. tuberculosis in vitro in monocytes and in mice by aminomethylene pyrazinamide analogs"],"prefix":"10.1016","volume":"88","author":[{"given":"Woo Jin","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Kornilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin H.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonid B.","family":"Heifets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Cynamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2008.06.001_bib1","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1016\/S0140-6736(07)61262-8","article-title":"Tuberculosis","volume":"370","author":"Maartens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2008.06.001_bib2","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrmicro1816","article-title":"Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis","volume":"6","author":"Sacchettini","year":"2008","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tube.2008.06.001_bib3","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.bmc.2007.01.030","article-title":"Antituberculosis drugs: ten years of research","volume":"15","author":"Janin","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.tube.2008.06.001_bib4","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nm0307-290","article-title":"Challenges in tuberculosis drug research and development","volume":"13","author":"Ginsberg","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2008.06.001_bib5","first-page":"150","article-title":"Action of nicotinamide on bacilli of the species Mycobacterium","volume":"220","author":"Chorine","year":"1945","journal-title":"C R Acad Sci"},{"key":"10.1016\/j.tube.2008.06.001_bib6","first-page":"1249","article-title":"The effect of nicotinic acid amide on experimental tuberculosis of white mice","volume":"33","author":"McKenzie","year":"1949","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.tube.2008.06.001_bib7","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1021\/ja01134a045","article-title":"Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds","volume":"74","author":"Kushner","year":"1952","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.tube.2008.06.001_bib8","series-title":"Antimicrobial therapy and vaccines","first-page":"668","article-title":"Pyrazinamide","author":"Heifets","year":"1999"},{"key":"10.1016\/j.tube.2008.06.001_bib9","first-page":"6","article-title":"The curious characteristics of pyrazinamide: a review","volume":"7","author":"Zhang","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2741\/1289","article-title":"Mechanisms of drug resistance in Mycobacterium tuberculosis","volume":"9","author":"Wade","year":"2004","journal-title":"Front Biosci"},{"key":"10.1016\/j.tube.2008.06.001_bib11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0041-3879(85)90040-6","article-title":"The action of antituberculosis drugs in short-course chemotherapy","volume":"66","author":"Mitchison","year":"1985","journal-title":"Tubercle"},{"key":"10.1016\/j.tube.2008.06.001_bib12","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1378\/chest.94.4.845","article-title":"The role of pyrazinamide in tuberculosis chemotherapy","volume":"94","author":"Steele","year":"1988","journal-title":"Chest"},{"key":"10.1016\/j.tube.2008.06.001_bib13","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/S0140-6736(04)17141-9","article-title":"Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial","volume":"364","author":"Jindani","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tube.2008.06.001_bib14","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1128\/AAC.41.3.540","article-title":"Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis","volume":"41","author":"Scorpio","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib15","first-page":"461","article-title":"Pyrazinamide susceptibility and amidase activity of tubercle bacilli","volume":"95","author":"Konno","year":"1967","journal-title":"Am Rev Resp Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/nm0696-662","article-title":"Mutations in pncA, a gene encoding pyrazinamidase\/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus","volume":"2","author":"Scorpio","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2008.06.001_bib17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1128\/AAC.33.8.1252","article-title":"Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?","volume":"33","author":"Heifets","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/AAC.39.6.1269","article-title":"Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide","volume":"39","author":"Speirs","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"Pt 6","key":"10.1016\/j.tube.2008.06.001_bib19","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1099\/13500872-145-6-1359","article-title":"Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity","volume":"145","author":"Raynaud","year":"1999","journal-title":"Microbiology"},{"key":"10.1016\/j.tube.2008.06.001_bib20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1128\/AAC.01369-06","article-title":"Pyrazinoic acid and its n-propyl ester inhibit Fatty Acid Synthase Type I in replicating tubercle bacilli","volume":"51","author":"Zimhony","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib21","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1128\/AAC.01458-06","article-title":"Inhibition of isolated Mycobacterium tuberculosis Fatty Acid Synthase I by pyrazinamide analogs","volume":"51","author":"Ngo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib22","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1021\/jm00020a003","article-title":"Pyrazinoic acid esters with broad spectrum in vitro antimycobacterial activity","volume":"20","author":"Cynamon","year":"1995","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2008.06.001_bib23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/AAC.42.2.462","article-title":"In vitro antimycobacterial activity of 5-chloropyrazinamide","volume":"42","author":"Cynamon","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib24","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1021\/jm950538t","article-title":"Quantitative structure\u2013activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters","volume":"39","author":"Bergmann","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2008.06.001_bib25","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1128\/AAC.39.9.2088","article-title":"In vitro antimycobacterial activities of pyrazinamide analogs","volume":"39","author":"Yamamoto","year":"1995","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.tube.2008.06.001_bib26","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1021\/jm9708745","article-title":"Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids","volume":"41","author":"Wachter","year":"1998","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2008.06.001_bib27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1021\/jm000350w","article-title":"Antimycobacterial activity of substituted isosteres of pyridine- and pyrazinecarboxylic acids. 2","volume":"44","author":"Gezginci","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2008.06.001_bib28","unstructured":"S.p.A. BIC. N-(Morpholinomethyl)amide of pyrazinecarboxylic acid. Belgium; 1962."},{"key":"10.1016\/j.tube.2008.06.001_bib29","first-page":"1704","article-title":"Basic derivatives of pyrazine-2-carboxylic acid with antimycobacterial action. Microbiological and pharmacological study","volume":"53","author":"Bonati","year":"1962","journal-title":"Minerva Med"},{"key":"10.1016\/j.tube.2008.06.001_bib30","first-page":"162","article-title":"Resistance and its delay as criterion of the antimycobacterial activity of morphazinamide and pyrazinamide under experimental conditions","volume":"27","author":"Havel","year":"1967","journal-title":"Rozhl Tuberk"},{"key":"10.1016\/j.tube.2008.06.001_bib31","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000220471","article-title":"Significance of intracellular medium for antimycobacterial activity of some pyrazine-2-carboxylic acid derivatives","volume":"11","author":"Solov'ev","year":"1966","journal-title":"Chemotherapia"},{"key":"10.1016\/j.tube.2008.06.001_bib32","first-page":"734","article-title":"Antituberculous properties of some pyrazinecarboxylic acid derivatives","volume":"30","author":"Solov'ev","year":"1967","journal-title":"Farmakol Toksikol (Moscow)"},{"key":"10.1016\/j.tube.2008.06.001_bib33","first-page":"1006","article-title":"Effect of pyrazinamde and morpholinomethyl pyrazinamide in the intracellular neutralization of tubercle bacilli in macrophages","volume":"72","author":"Bertoni","year":"1965","journal-title":"Clin Med"},{"key":"10.1016\/j.tube.2008.06.001_bib34","first-page":"2771","article-title":"Bacteriological and pharmacological kinetic aspects of morphazinamide bacteriological and pharmacological kinetic aspects of morphazinamide","volume":"56","author":"Lucchesi","year":"1965","journal-title":"Minerva Med"},{"key":"10.1016\/j.tube.2008.06.001_bib35","first-page":"49","article-title":"Comparison of the therapeutic action of morphazinamide and pyrazinamide associated with ethionamide in experimental tuberculosis in guinea pigs","volume":"14","author":"Rozewska","year":"1967","journal-title":"G Ital Chemioter"},{"key":"10.1016\/j.tube.2008.06.001_bib36","first-page":"2900","article-title":"Clinical experience with morphazinamide","volume":"56","author":"Casalone","year":"1965","journal-title":"Minerva Med"},{"key":"10.1016\/j.tube.2008.06.001_bib37","first-page":"266","article-title":"Results of the treatment of tuberculosis with the new drugs isoxyl, ethambutol, rifamycin, and morphazinamide","volume":"117","author":"Daddi","year":"1967","journal-title":"Wien Med Wochenschr"},{"key":"10.1016\/j.tube.2008.06.001_bib38","first-page":"722","article-title":"Comparative studies of tuberculostatic activity of N-morpholinomethyl pyrazinamide and pyrazine 2-carboxamide in vitro and in vivo","volume":"13","author":"Freerksen","year":"1963","journal-title":"Arzneimittel Forsch"},{"key":"10.1016\/j.tube.2008.06.001_bib39","first-page":"2759","article-title":"Metabolism of morphazinamide in patients with pulmonary tuberculosis metabolism of morphazinamide in patients with pulmonary tuberculosis","volume":"56","author":"Zierski","year":"1965","journal-title":"Minerva Med"},{"key":"10.1016\/j.tube.2008.06.001_bib40","first-page":"773","article-title":"Metabolism of morphazinamide in the treatment of chronic pulmonary tuberculosis metabolism of morphazinamide in the treatment of chronic pulmonary tuberculosis","volume":"33","author":"Zierski","year":"1965","journal-title":"Gruzlica"},{"key":"10.1016\/j.tube.2008.06.001_bib41","first-page":"1225","article-title":"Aminomethyl amides of pyrazinecarboxylic acids \u2013 (I) latent forms of chemotherapeutically active principles","volume":"14","author":"Felder","year":"1964","journal-title":"Arzneimittel Forsch"},{"key":"10.1016\/j.tube.2008.06.001_bib42","first-page":"76","article-title":"Specificity of antituberculous action in vitro of pyrazine-2-carboxylic acid derivatives","author":"Pavlov","year":"1971","journal-title":"Probl Tuberk"},{"key":"10.1016\/j.tube.2008.06.001_bib43","first-page":"261","article-title":"Role of formaldehyde in the antimycobacterial action of morphazinamide in vitro","volume":"20","author":"Castelli","year":"1966","journal-title":"G Ital Mal Torace"},{"key":"10.1016\/j.tube.2008.06.001_bib44","first-page":"2762","article-title":"Metabolic degradation of morphazinamide metabolic degradation of morphazinamide","volume":"56","author":"Gialdroni-Grassi","year":"1965","journal-title":"Minerva Med"},{"key":"10.1016\/j.tube.2008.06.001_bib45","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0041-3879(75)90054-9","article-title":"Reappraisal of the activity of morphazinamide against M. tuberculosis","volume":"56","author":"Bravo","year":"1975","journal-title":"Tubercle"},{"key":"10.1016\/j.tube.2008.06.001_bib46","first-page":"58","article-title":"The antituberculous activity of morphazinamide","volume":"10","author":"Lucchesi","year":"1963","journal-title":"G Ital Chemioter"},{"key":"10.1016\/j.tube.2008.06.001_bib47","unstructured":"Mariani B. Hepatotoxicity and tuberculosis therapy, lack of hepatotoxicity of morphazinamide. Progress in antimicrobial and anticancer chemotherapy. Proceedings of the 6th International Congress on Chemotherapy, Baltimore MD; 1969, p. 617\u201320."},{"key":"10.1016\/j.tube.2008.06.001_bib48","first-page":"2782","article-title":"Observations in humans and animals of hepatic function, gastric secretion, and uricemia during morphazineamide therapy","volume":"56","author":"Mariani","year":"1965","journal-title":"Minerva Med"},{"key":"10.1016\/j.tube.2008.06.001_bib49","first-page":"140","article-title":"Toxicity of morphazinamide compared with pyrazinamide","volume":"6","author":"Zitkova","year":"1983","journal-title":"Czech Med"},{"key":"10.1016\/j.tube.2008.06.001_bib50","first-page":"491","article-title":"Pyrazinamide is not active against M. tuberculosis in human monocyte-derived macrophages","volume":"4","author":"Heifets","year":"2000","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1179\/joc.1995.7.3.207","article-title":"Methods for determining concentrations of antimicrobial agents in human monocytes","volume":"7","author":"Mor","year":"1995","journal-title":"J Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib52","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1128\/AAC.38.5.1161","article-title":"Inhibitory and bactericidal activities of levofloxacin against M. tuberculosis in vitro and in human macrophages","volume":"38","author":"Mor","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib53","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1161\/01.ATV.0000086961.44581.B7","article-title":"Tumor necrosis factor-\u03b1 promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms","volume":"23","author":"Boyle","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.tube.2008.06.001_bib54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0002-9440(10)62526-6","article-title":"Suppression by apoptotic cells defines tumor necrosis factor-mediated induction of glomerular mesangial cell apoptosis by activated macrophages","volume":"159","author":"Duffield","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.tube.2008.06.001_bib55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/cimm.2000.1687","article-title":"Influence of alternatively and classically activated macrophages on fibrogenic activities of human fibroblasts","volume":"204","author":"Song","year":"2000","journal-title":"Cell Immunol"},{"key":"10.1016\/j.tube.2008.06.001_bib56","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1126\/science.8456300","article-title":"Multiple defects of immune cell function in mice with disrupted interferon-gamma genes","volume":"259","author":"Dalton","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.tube.2008.06.001_bib57","first-page":"748","article-title":"Activation of pyrazinamide and nicotinamide in acidic environments in vitro","volume":"70","author":"McDermott","year":"1954","journal-title":"Am Rev Tuberc"},{"key":"10.1016\/j.tube.2008.06.001_bib58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1099\/0022-1317-51-1-42","article-title":"Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide","volume":"51","author":"Zhang","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.tube.2008.06.001_bib59","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1099\/jmm.0.45639-0","article-title":"Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis","volume":"53","author":"Wade","year":"2004","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.tube.2008.06.001_bib60","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/jac\/dkh042","article-title":"Iron enhances the antituberculous activity of pyrazinamide","volume":"53","author":"Somoskovi","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib61","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/AAC.32.7.1002","article-title":"Determination of pyrazinamide MIC at different pHs by the radiometric method","volume":"32","author":"Salfinger","year":"1988","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.tube.2008.06.001_bib62","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1128\/JB.181.7.2044-2049.1999","article-title":"Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide","volume":"181","author":"Zhang","year":"1999","journal-title":"J Bacteriol"},{"key":"10.1016\/j.tube.2008.06.001_bib63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0196-4399(85)80012-X","article-title":"Identification and drug susceptibility test results for Mycobacteria species","volume":"7","author":"Good","year":"1985","journal-title":"Clin Microbiol Newslett"},{"key":"10.1016\/j.tube.2008.06.001_bib64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/jac\/dkg287","article-title":"Susceptibility of Mycobacterium tuberculosis to weak acids","volume":"52","author":"Zhang","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib65","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jac\/dkl358","article-title":"Effects of weak acids, UV and proton motive force inhibitors on pyrazinamide activity against Mycobacterium tuberculosis in vitro","volume":"58","author":"Wade","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib66","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1164\/arrd.1986.134.5.1052","article-title":"Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages","volume":"134","author":"Crowle","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib67","first-page":"718","article-title":"The intracellular activation of pyrazinamide and nicotinamide","volume":"74","author":"Mackaness","year":"1956","journal-title":"Am Rev Tuberc"},{"key":"10.1016\/j.tube.2008.06.001_bib68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/infdis\/162.1.201","article-title":"Pyrazinamide and pyrazinoic acid activity against tubercle bacilli in cultured human macrophages and in the BACTEC system","volume":"162","author":"Salfinger","year":"1990","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib69","first-page":"460","article-title":"Bestimmung der empfindlichkeit von Tuberkulosebacterien gegen\u00fcber Pyrazinamid mit Hilfe humaner Makophagenkultur","volume":"44","author":"Salfinger","year":"1990","journal-title":"Pneumologie"},{"key":"10.1016\/j.tube.2008.06.001_bib70","first-page":"1274","article-title":"Killing of macrophage-ingested mycobacteria by rifampicin, pyrazinamide, and pyrazinoic acid alone and in combination","volume":"132","author":"Carlone","year":"1985","journal-title":"Am Rev Resp Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib71","first-page":"1268","article-title":"The penetration of rifampacin, pyrazinamide, and pyrazinoic acid into mouse macrophages","volume":"132","author":"Acocella","year":"1985","journal-title":"Am Rev Resp Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib72","first-page":"552","article-title":"Phagocytosis of M. tuberculosis and M. smegmatis stained with indicator dyes","volume":"74","author":"Sprick","year":"1956","journal-title":"Am Rev Tuberc"},{"key":"10.1016\/j.tube.2008.06.001_bib73","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1126\/science.8303277","article-title":"Lack of acidification in Mycobacterium phagosome produced by exclusion of the vesicular proton-ATPase","volume":"263","author":"Sturgill-Koszycki","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.tube.2008.06.001_bib74","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1128\/AAC.32.2.287","article-title":"Pyrazinamide is not effective against intracellularly growing M. tuberculosis","volume":"32","author":"Rastogi","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib75","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1128\/AAC.34.11.2217","article-title":"Inhibition of tubercle bacilli in cultured human macrophages by chloroquine used alone and in combination with streptomycin, isoniazid, pyrazinamide, and two metabolites of vitamin D3","volume":"34","author":"Crowle","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib76","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1164\/ajrccm\/146.6.1448","article-title":"The combined effect of rifampin and pyrazinamide within the human macrophage","volume":"146","author":"Sbarbaro","year":"1992","journal-title":"Am Rev Resp Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib77","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0962-8479(96)90045-3","article-title":"Combined effect of pyrazinamide and ofloxacin within the human macrophage","volume":"77","author":"Sbarbaro","year":"1996","journal-title":"Tuber Lung Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib78","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/0007-0971(84)90165-7","article-title":"A controlled trial of 6months chemotherapy in pulmonary tuberculosis. Final report: results during 36months after the end of chemotherapy and beyond","volume":"78","author":"Society BT","year":"1984","journal-title":"Br J Dis Chest"},{"key":"10.1016\/j.tube.2008.06.001_bib79","first-page":"579","article-title":"Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis","volume":"119","year":"1979","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib80","first-page":"1091","article-title":"Supervised six months treatment of newly diagnosed pulmonary tuberculosis using isonizid, rifampicin and pyrazinamide with and without streptomycin","volume":"130","author":"Snider","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib81","first-page":"265","article-title":"Successful intermittent treatment of smear positive pulmonary tuberculosis in six months: a cooperative study in Poland","volume":"125","author":"Snider","year":"1982","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2008.06.001_bib82","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/AAC.40.1.14","article-title":"Activity of pyrazinamide in a murine model against Mycobacterium tuberculosis isolates with various levels of in vitro susceptibility","volume":"40","author":"Klemens","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib83","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1084\/jem.104.5.763","article-title":"The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique: II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug","volume":"104","author":"McCune","year":"1956","journal-title":"J Exp Med"},{"key":"10.1016\/j.tube.2008.06.001_bib84","first-page":"5","article-title":"The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy","volume":"53","author":"Grosset","year":"1978","journal-title":"Bull Int Union Against Tuberc"},{"key":"10.1016\/j.tube.2008.06.001_bib85","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1128\/AAC.38.10.2245","article-title":"Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model","volume":"38","author":"Klemens","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib86","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1128\/AAC.40.12.2809","article-title":"Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis","volume":"40","author":"Kelly","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib87","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1128\/AAC.44.11.3167-3168.2000","article-title":"Evaluation of Rifalazil in a combination treatment regimen as an alternative to Isoniazid\u2013Rifampin therapy in a mouse tuberculosis model","volume":"44","author":"Lenaerts","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2008.06.001_bib88","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1128\/AAC.44.6.1458-1462.2000","article-title":"Evaluation of Rifalazil in long-term treatment regimens for tuberculosis in mice","volume":"44","author":"Shoen","year":"2000","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979208000668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979208000668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T12:13:26Z","timestamp":1588853606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979208000668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":88,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S1472979208000668"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2008.06.001","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}